Resistance to Oral Therapy in Lung Cancer

Plain-language summary

This study investigated molecular alterations related to treatment resistance in blood samples from lung cancer patients treated with Osimertinib. It enrolled patients with advanced non-small cell lung cancer who had activating EGFR mutations (exon 19 deletions or exon 21 L858R). This is a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Montpellier

Intervention

Description of the molecular alterations detected in blood samples of patients treated by osimertinib

Start date

7/1/2017

Estimated completion

11/28/2020

Countries

France

Related genes

Locations

• Montpellier, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* advanced non-small cell lung cancer stage IIIB/IV
* Documentation of activating EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations) at the time of initial diagnosis
* Patient may receive up to one line of third EGFR TKI
* Plasma sample testing performed to detect EGFR TKI resistance

Exclusion Criteria:

* Patients have other concurrent cancers
* Patients who are not eligible receive TKI